Clearance Summary
CARDIOZYME CK-CONTROL ABNORMAL received FDA 510(k) clearance under submission number K770971, sponsored by Dade, Baxter Travenol Diagnostics, Inc.. The device was reviewed via the Traditional premarket notification pathway and assigned to the Clinical Chemistry review panel. The statutory decision date of record is 1977-08-04.
- Submission: K770971
- Applicant / Sponsor: Dade, Baxter Travenol Diagnostics, Inc.
- Clearance pathway: Traditional
- Review panel: Clinical Chemistry
- Device class: Class I
- Regulation citation: 21 CFR 862.1660
- Decision date: 1977-08-04
Classification & Regulation
This clearance is catalogued under FDA product code JJT and 21 CFR 862.1660, within the Clinical Chemistry review panel as a Class I device.